Literature DB >> 29710267

Association Between Cystatin C and 20-Year Cumulative Incidence of Hearing Impairment in the Epidemiology of Hearing Loss Study.

Carla R Schubert1, Adam J Paulsen1, David M Nondahl1, Dayna S Dalton1, Mary E Fischer1, Barbara E K Klein1, Ronald Klein1, Ted S Tweed1, Karen J Cruickshanks1,2.   

Abstract

Importance: Hearing impairment (HI) is one of the most common conditions affecting older adults. Identification of factors associated with the development of HI may lead to ways to reduce the incidence of this condition. Objective: To investigate the association between cystatin C, both as an independent biomarker and as a marker of kidney function, and the 20-year incidence of HI. Design, Setting, and Participants: Data were obtained from the Epidemiology of Hearing Loss Study (EHLS), a longitudinal, population-based study in Beaver Dam, Wisconsin. Baseline examinations began in 1993 and continued through 1995, and participants were examined approximately every 5 years, with the most recent examination phase completed in 2015. The EHLS participants with serum cystatin C concentration data and without HI at the baseline examination were included in this study. Main Outcomes and Measures: Participants without HI were followed up for incident HI (pure-tone average of hearing thresholds at 0.5, 1, 2, and 4 kHz >25 dB hearing level in either ear) for 20 years. Cystatin C was analyzed as a biomarker (concentration) and used to determine estimated glomerular filtration rate (eGFRCysC). Discrete-time Cox proportional hazards regression models were used to analyze the association between cystatin C concentration and eGFRCysC and the 20-year cumulative incidence of HI.
Results: There were 863 participants aged 48 to 86 years with cystatin C data and without HI at baseline. Of these, 599 (69.4%) were women. In models adjusted for age and sex, cystatin C was associated with an increased risk of developing HI (hazard ratio [HR], 1.20; 95% CI, 1.07-1.34 per 0.2-mg/L increase in cystatin C concentration), but the estimate was attenuated after further adjusting for educational level, current smoking, waist circumference, and glycated hemoglobin (HR, 1.11; 95% CI, 0.98-1.27 per 0.2-mg/L increase in cystatin C concentration). Low eGFRCysC was significantly associated with the 20-year cumulative incidence of HI in both the age- and sex-adjusted model (HR, 1.70; 95% CI, 1.16-2.48; <60 vs ≥60 mL/min/1.73 m2) and the multivariable-adjusted model (HR, 1.50; 95% CI, 1.02-2.22; <60 vs ≥60 mL/min/1.73 m2). Conclusions and Relevance: Reduced kidney function as estimated using cystatin C, but not cystatin C alone, was associated with the 20-year cumulative incidence of HI, suggesting that some age-related HI may occur in conjunction with or as the result of reduced kidney function.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29710267      PMCID: PMC6014887          DOI: 10.1001/jamaoto.2018.0041

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  41 in total

Review 1.  Uremia.

Authors:  Timothy W Meyer; Thomas H Hostetter
Journal:  N Engl J Med       Date:  2007-09-27       Impact factor: 91.245

2.  The hypertension detection and follow-up program: Hypertension detection and follow-up program cooperative group.

Authors: 
Journal:  Prev Med       Date:  1976-06       Impact factor: 4.018

3.  Cystatin C versus creatinine in determining risk based on kidney function.

Authors:  Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

4.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

5.  Association of NIDDM and hearing loss.

Authors:  D S Dalton; K J Cruickshanks; R Klein; B E Klein; T L Wiley
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

6.  Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Anna Köttgen; Elizabeth Selvin; Lesley A Stevens; Andrew S Levey; Frederick Van Lente; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

7.  Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland.

Authors:  Melanie K Haroun; Bernard G Jaar; Sandra C Hoffman; George W Comstock; Michael J Klag; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

8.  Education, occupation, noise exposure history and the 10-yr cumulative incidence of hearing impairment in older adults.

Authors:  Karen J Cruickshanks; David M Nondahl; Ted S Tweed; Terry L Wiley; Barbara E K Klein; Ronald Klein; Rick Chappell; Dayna S Dalton; Scott D Nash
Journal:  Hear Res       Date:  2009-10-22       Impact factor: 3.208

Review 9.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

10.  The Beaver Dam Eye Study: visual acuity.

Authors:  R Klein; B E Klein; K L Linton; D L De Mets
Journal:  Ophthalmology       Date:  1991-08       Impact factor: 12.079

View more
  4 in total

1.  Chronic kidney disease and the risk of incident hearing loss.

Authors:  Shruti Gupta; Sharon G Curhan; Karen J Cruickshanks; Barbara E K Klein; Ronald Klein; Gary C Curhan
Journal:  Laryngoscope       Date:  2019-05-28       Impact factor: 3.325

2.  Neuroprotective factors and incident hearing impairment in the epidemiology of hearing loss study.

Authors:  Adam J Paulsen; Karen J Cruickshanks; Alex Pinto; Carla R Schubert; Dayna S Dalton; Mary E Fischer; Barbara E K Klein; Ronald Klein; Michael Y Tsai; Ted S Tweed
Journal:  Laryngoscope       Date:  2019-01-30       Impact factor: 3.325

3.  RISK FACTORS FOR HEARING IMPAIRMENT IN TYPE 1 DIABETES.

Authors:  Barbara H Braffett; Gayle M Lorenzi; Catherine C Cowie; Xiaoyu Gao; Kathleen E Bainbridge; Karen J Cruickshanks; John R Kramer; Rose A Gubitosi-Klug; Mary E Larkin; Annette Barnie; John M Lachin; David S Schade
Journal:  Endocr Pract       Date:  2019-08-14       Impact factor: 3.443

4.  Clinical features and hearing prognosis of idiopathic sudden sensorineural hearing loss in patients undergoing hemodialysis: A retrospective study.

Authors:  Kengo Yamamoto; Takaomi Kurioka; Shogo Furuki; Hajime Sano; Kentaro Ohashi; Motofumi Ohki; Taku Yamashita
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-08-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.